Document Detail

Clinical efficacy and electrophysiologic effects of cibenzoline therapy in patients with ventricular arrhythmias.
MedLine Citation:
PMID:  6693656     Owner:  NLM     Status:  MEDLINE    
Cibenzoline, a new antiarrhythmic agent, was tested in 26 patients who had symptomatic ventricular tachycardia (24 patients) or premature ventricular complexes (2 patients) unresponsive to conventional drugs. Cibenzoline was given orally every 8 hours to maximal doses of 65 mg in 2 patients, 81.25 mg in 22 patients and 97.5 mg in 2 patients. Cibenzoline abolished spontaneous episodes of ventricular tachycardia in 8 of 16 patients with ventricular tachycardia during a 72 hour control electrocardiographic recording, and 7 of 22 patients had greater than 83% decrease in premature ventricular complexes compared with control. The PR interval increased 14% (p less than 0.001), QRS duration increased 17% (p less than 0.001), QT interval did not change and mean ejection fraction in 10 patients did not change. Electrophysiologic studies were performed on 10 patients in the control period and during maximal cibenzoline dosage. Cibenzoline did not affect electrophysiologic properties of the atrium or atrioventricular (AV) node. It prolonged the ventricular effective (223 +/- 16 to 241 +/- 22 ms, p less than 0.02) and functional (247 +/- 18 to 264 +/- 25 ms, p less than 0.02) refractory periods. At control electrophysiologic studies, ventricular tachycardia was induced in 9 of 10 patients (mean cycle length 210 +/- 31 ms). Cibenzoline therapy prevented ventricular tachycardia induction in two patients, and in the other seven patients the mean ventricular tachycardia cycle length increased from 210 to 260 ms. The one patient with no ventricular arrhythmia induced during the control study still had no arrhythmia induced while receiving cibenzoline.(ABSTRACT TRUNCATED AT 250 WORDS)
K F Browne; E N Prystowsky; D P Zipes; D A Chilson; J J Heger
Related Documents :
15610916 - Long-term follow-up of patients with p-r prolongation after catheter ablation of slow p...
9271286 - Evaluation of a protocol to select patients of all ages for cardioversion from atrial f...
1701896 - Vasovagal syncope: diagnostic role of head-up tilt test in patients with positive ocula...
8160596 - The impact of left ventricular dysfunction on outcomes with the implantable defibrillator.
19473636 - Natural history and impact on outcomes of acute kidney injury in patients with road tra...
22738686 - Toward understanding the difference between using patients or encounters in the account...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  3     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1984 Mar 
Date Detail:
Created Date:  1984-03-23     Completed Date:  1984-03-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  857-64     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / adverse effects,  therapeutic use*
Arrhythmias, Cardiac / drug therapy*
Cardiac Pacing, Artificial
Follow-Up Studies
Heart / physiopathology
Heart Ventricles / physiopathology
Hemodynamics / drug effects
Imidazoles / adverse effects,  therapeutic use*
Middle Aged
Grant Support
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Imidazoles; 53267-01-9/cifenline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Absence of the aortic valve: antenatal and postnatal two-dimensional and Doppler echocardiographic f...
Next Document:  Right to left intracardiac shunt: a unique presentation of metastatic cardiac disease.